Vital Therapies seeks $86.25m for cell therapy via artificial liver
This article was originally published in Clinica
Executive Summary
Vital Therapies said in September that a multi-tranche $76m venture funding commitment would fund the Phase III program for its human allogeneic cellular therapy for the treatment of acute liver failure (www.clinica.co.uk, 1 October 2012). Now the San Diego-based company is seeking up to $86.25m in an initial public offering to complete three late-stage clinical trials for its stem cell-based, bio-artificial liver therapy called ELAD.